Recent Developments In Empty Capsules Industry

In February 2025, Roquette expanded its global appearance by opening a new production facility in Germany, focusing on producing HPMC capsules. The function is part of the rocket's strategy to meet the increasing demand for plant-based, vegetarian, and permanent capsule solutions in the pharmaceutical and neutrality industries. By increasing production capacity, Roquette aims to complete the consumer's priority for environmentally friendly and morally produced products.

In May 2025, Qualicaps, which is now under the umbrella of the rocket, launched the next generation of capsules, designed to improve efficiency by filling the delicate powder word. This innovation is ready to streamline production lines and increase the company's ability to handle more complex drug delivery systems. By improving the filling process, the goal of profits is to meet the increasing demand for refined and innovative drug products that require accuracy and delicacy during production.

In February 2024, Capsugel introduced Enprotect, which was a new capsule designed for delayed relief and intestinal-targeted drug distribution. This innovation was developed to meet the challenge of improving the bioavailability of poorly soluble medicines. Enprotect capsules represent a significant progression in drug distribution technologies that make them particularly useful for patients who need more targeted treatments. Technology expanded the capacity of capsules in the special capsule market, providing a valuable tool for pharmaceutical companies to develop more effective agents that increase patient results. The move also postponed the ongoing trend in the industry to improve the distribution of medicines through more accurate and sewn solutions.

In December 2024, Lonza made a strategic decision to get out of the business of capsules and health materials (CHIS), which quoted the demand for drug supply after the COVID-19 epidemic. This change reflects the company's plan to resume its business to its most important contract development and production organization (CDMO). While the complete information about the exit is expected to be explained in 2025, the step reflects the desire to stream out the operation of Lonza and focus on its most advantageous and forward-looking companies. This decision also reflects the changed dynamics of the pharmaceutical industry as companies accommodate the pandemic after new market realities.

In April 2023, Qualicaps launched a new line of HPMC (hydroxypropyl methylcellulose) capsules, aimed at meeting the rising demand for plant-based and vegan capsules. This innovation was a direct response to the increasing consumer preference for plant-derived products in the pharmaceutical and nutraceutical sectors. The shift toward plant-based products has been growing rapidly, and Qualicaps’ new HPMC capsules allowed the company to stay ahead of the curve by offering an alternative to traditional gelatin capsules. This development was part of a larger trend within the industry to move towards more sustainable and ethical production practices, reflecting the growing awareness around health, sustainability, and environmental impact.

Impact of Recent developments in Empty Capsules Industry

Impact of Recent developments in Empty Capsules Industry

Roquette’s decision to open a new manufacturing facility focused on HPMC capsules is a direct response to the rising demand for plant-based and sustainable solutions in the pharmaceutical and nutraceutical sectors. The increased capacity will allow the company to meet the growing consumer preference for environmentally friendly products, particularly those that are vegan and plant-derived. This expansion will likely lead to a larger market share for Roquette in the HPMC capsule segment, as it strengthens its position as a key supplier of sustainable capsule solutions. This move also aligns with the broader industry trend towards sustainability, which is becoming a critical factor for consumers and manufacturers alike. To optimize purchasing in the empty capsules industry, companies can focus on strategic sourcing, such as leveraging bulk purchasing, long-term supplier agreements, and staying informed about material innovations like HPMC and plant-based alternatives. By carefully selecting suppliers that align with both sustainability goals and production requirements, businesses can secure high-quality, cost-effective solutions while navigating the fluctuations in pricing and demand. As sustainability and technological advancements continue to drive the market, companies that adopt these purchasing strategies will be well-positioned to take advantage of emerging opportunities in the evolving empty capsules landscape.

The launch of next-generation capsule fillers by Qualicaps is set to transform the efficiency and precision with which delicate powder formulations are filled into capsules. This innovation will streamline production lines and improve the handling of more complex drug delivery systems. The improved filling process can significantly reduce manufacturing time and costs while increasing the quality and consistency of the capsules.

Capsugel’s introduction of Enprotect capsules for delayed-release and intestinal-targeted drug delivery adds a new dimension to the empty capsule market. This technology addresses the growing need for capsules that can improve the bioavailability of poorly soluble drugs, which is a significant challenge in modern pharmaceuticals. By offering a solution for more effective drug delivery, Enprotect capsules enable pharmaceutical companies to produce drugs that provide better outcomes for patients, especially for those with complex treatment regimens.

Lonza’s strategic decision to exit the Capsules and Health Ingredients (CHI) business will have notable implications for the empty capsules market. As one of the leading players in the capsule production industry, Lonza's exit signals a realignment of priorities and resources. The company's refocus on its core Contract Development and Manufacturing Organization (CDMO) business may result in less competition in the capsules space, which could create opportunities for other players, such as Roquette and Qualicaps, to capture a larger market share.

The launch of HPMC capsules by Qualicaps in 2023 reflects the growing demand for plant-based and vegan capsule alternatives. This innovative technologies directly responds to the increasing consumer shift towards sustainability and ethical consumption. As more consumers seek products that align with their values, pharmaceutical and nutraceutical companies are under pressure to provide plant-derived solutions. HPMC capsules are increasingly viewed as a viable alternative to traditional gelatin capsules, and their introduction into the market represents a significant step toward meeting this demand.

Source: